L3VLUP
ProSign in

BDTX in the 13F filings

Black Diamond Therapeutics Inc · CUSIP 09203E105

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q4 2025Q4 2023Q3 2023Q2 2023Q3 2021Q2 2021Q1 2021Q4 2020Q3 2020Q2 2020Q1 2020
Quarter end
30 Jun 2021
the date the book describes
Filed
16 Aug 2021
latest of these filings; the earliest 16 Aug 2021
Managers listing it
2
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q1 2021 and Q2 2021; 1 listed it in both
Shares listed
209,629
combined, among listed positions
Reported value
$2.6m
combined, at the quarter end

Managers listing BDTX in Q2 2021

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q1 2021, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

2 of 2 holders

ActionFiling
PDT Partners LLC111,967$1.4m0.09%Added+44,22316 Aug 2021 (the filing on sec.gov)
Walleye Capital LLC97,662$1.2munder 0.1%Newnew16 Aug 2021 (the filing on sec.gov)

Largest increases and reductions, by shares

Q1 2021 to Q2 2021, among managers that listed it in both quarters or opened it.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
3 in Q4 2020 to 1 in Q4 2025

Tracked managers listing it, at least.

0123Q1 2020Q2 2020Q3 2020Q4 2020Q1 2021Q2 2021Q3 2021Q2 2023Q3 2023Q4 2023Q4 2025
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
BDTX by quarter
QuarterHoldersReported valueBuyersSellers
Q1 20202$14mn.a.n.a.
Q2 20201$22mn.a.n.a.
Q3 20201$16mn.a.n.a.
Q4 20203$37mn.a.n.a.
Q1 20211$1.6mn.a.n.a.
Q2 20212$2.6mn.a.n.a.
Q3 20211$862kn.a.n.a.
Q2 20231$252kn.a.n.a.
Q3 20232$5.0mn.a.n.a.
Q4 20231$4.4m02
Q4 20251$1.0m134

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

BDTX and GILD →BDTX and AMGN →BDTX and ARGX →Choose a stock to compare with BDTX →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own BDTX, latest filings →Back to the 13F Explorer →